NICE approves extra ‘triple therapy’ drug for diabetes
Regulator recommends dapagliflozin in triple therapy Related items fromOnMedica Glycosylated haemoglobin (HbA1c) and screening for diabetes Diabetes drugs costs NHS England nearly £1bn a year Intensive treatment of type 2 diabetes with microalbuminuria reaps benefits NICE guidance delays hinder good diabetes care Diabetes prescriptions rise by a third in last five years
Source: OnMedica Latest News - Category: UK Health Source Type: news
More News: Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | National Institute for Health and Clinical Excelle | UK Health